Blog

  • Navepegritide demonstrates growth velocity, skeletal alignment in children with achondroplasia

    Navepegritide demonstrates growth velocity, skeletal alignment in children with achondroplasia

    Takeaways

    • Navepegritide increased annualized growth velocity at 52 weeks compared with placebo.
    • Treatment improved skeletal alignment, including tibial-femoral angle and mechanical axis deviation.
    • Health-related quality of life measures showed…

    Continue Reading

  • iQOO 15’s global model picks up first software update following international rollout

    iQOO 15’s global model picks up first software update following international rollout

    The iQOO 15 began its international rollout a few days ago, starting with India, where it is receiving its first software update.

    The update carries firmware version PD2505F_EX_A_16.0.18.4.W30 and requires a download of over 750MB. It…

    Continue Reading

  • Yes, Really. This 98-Inch TCL TV Is Still Just $1,000 After Black Friday

    Yes, Really. This 98-Inch TCL TV Is Still Just $1,000 After Black Friday

    TCL televisions are known for offering fantastic value and among the many Black Friday deals that are still available, this one continues to amaze us. If you’re looking for a level of quality and reliability that’s way above the price you’ll be…

    Continue Reading

  • Top Infectious Disease News Stories Week of November 22 – November 28

    Top Infectious Disease News Stories Week of November 22 – November 28

    Patient With Novel Strain of Avian Influenza Dies

    A Grays Harbor County, WA resident who was undergoing treatment for H5N5 (avian influenza) died on November 21, the Washington State Department of Health reported. Interestingly, testing at the…

    Continue Reading

  • Tottenham Hotspur U18 2 – 2 Under 18 – Match Report

    Tottenham Hotspur U18 2 – 2 Under 18 – Match Report

    Our under-18s left with a hard-fought point after a 2-2 draw to Tottenham Hotspur in the U18 Premier League South on Saturday.

    In the match at Tottenham Hotspur Academy Spurs Lodge, Cedeach O’Neill put us ahead early on before a Luca…

    Continue Reading

  • New Nasal Nanodrops Eradicate Brain Tumors in Mice – SciTechDaily

    1. New Nasal Nanodrops Eradicate Brain Tumors in Mice  SciTechDaily
    2. Nasal drops fight brain tumors noninvasively  WashU Medicine
    3. A simple nasal drop could help battle deadly brain cancer; researchers explain how it works  The Times of India
    4. The simple…

    Continue Reading

  • Messages of concern, prayers pour in as Khaleda’s condition remains critical

    Messages of concern, prayers pour in as Khaleda’s condition remains critical

    Khaleda’s physical condition, at this time, is critical, and she is not in a state to be taken abroad for treatment, although the Zia family is keen to move her to London for advanced…

    Continue Reading

  • Los Gallos’ title defence in doubt after tricky Abu Dhabi opener – SailGP

    1. Los Gallos’ title defence in doubt after tricky Abu Dhabi opener  SailGP
    2. Ben Ainslie: There’s $2m up for grabs and real jeopardy in SailGP finale  The Telegraph
    3. Bet365 New Customer Offer For The SailGP Championship Final in Abu Dhabi (New Users…

    Continue Reading

  • Why Analysts See Lundin Gold’s Story Shifting With Higher Price Targets and Gold Forecasts

    Why Analysts See Lundin Gold’s Story Shifting With Higher Price Targets and Gold Forecasts

    The consensus analyst price target for Lundin Gold has risen slightly from CA$92.17 to CA$93.42, highlighting modestly increased expectations for the company’s fair value. This change comes amid more optimistic forecasts for gold and silver prices, and it reflects recent analyst reassessments of the sector. Stay tuned to find out how investors and analysts can keep informed about the evolving outlook for Lundin Gold.

    Analyst Price Targets don’t always capture the full story. Head over to our Company Report to find new ways to value Lundin Gold.

    🐂 Bullish Takeaways

    • BMO Capital increased its price target for Lundin Gold to C$104 from C$93 and maintained a Market Perform rating. This price target revision signals recognition of recent operational execution and market performance.

    • CIBC made a more substantial adjustment by raising its price target to C$116 from C$85. This reflects higher future gold and silver price forecasts, with CIBC now projecting gold at $4,500 per ounce and silver at $55 per ounce in 2026 and 2027.

    • These target increases are largely attributed to industry-wide updates in commodity price outlooks, rewarding Lundin Gold’s year-to-date stock outperformance and ongoing resilience in cost management.

    🐻 Bearish Takeaways

    • Despite the revised, more aggressive price targets, both CIBC and BMO Capital have maintained neutral stances (Neutral and Market Perform ratings, respectively). This indicates that some analysts believe current valuation already reflects much of the near-term upside.

    • CIBC notes that recent recommended price changes are in part a “catch-up” to reflect recent gold price movements, rather than a fundamental shift in expectations for the company’s execution or intrinsic value.

    Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there’s more to the story. Head to the Simply Wall St Community to discover more perspectives or begin writing your own Narrative!

    TSX:LUG Community Fair Values as at Nov 2025
    • Lundin Gold reported strong results from exploration drilling at Fruta del Norte, making progress toward an initial Mineral Reserve estimate expected in early 2026. The company also achieved Reserve replacement in both 2023 and 2024, highlighting ongoing resource growth.

    • Positive drilling outcomes were announced at the Sandia, Trancaloma, and Castillo targets, with the discovery of new high-grade mineralized zones and further expansion potential in all directions.

    • For the third quarter and year-to-date 2025, Lundin Gold posted higher ore processing and gold recovery rates. Despite these improvements, the average head grade and doré output were slightly lower compared to the previous year.

    • A leadership change was announced. Ron Hochstein will step down as President, CEO and Director, with Jamie Beck appointed as new CEO effective November 7, 2025.

    Continue Reading

  • What Catalysts Could Shift the Story for TI Amid Margin Pressures and Tariff Uncertainty

    What Catalysts Could Shift the Story for TI Amid Margin Pressures and Tariff Uncertainty

    Texas Instruments’ price target remains steady, reflecting confidence in the company’s long-term fundamentals despite shifting economic conditions. Analyst sentiment incorporates a mix of optimism around disciplined inventory management as well as cautiousness due to margin pressures and muted growth visibility. Stay tuned to see how you can monitor ongoing updates to the Texas Instruments investment narrative.

    Analyst Price Targets don’t always capture the full story. Head over to our Company Report to find new ways to value Texas Instruments.

    Recent analyst commentary on Texas Instruments reflects a diverse range of perspectives on the company’s current positioning and outlook. Below, we synthesize the main themes from the latest research updates.

    🐂 Bullish Takeaways

    • Rosenblatt maintains a Buy rating for Texas Instruments, noting disciplined management even in the face of operational headwinds. Despite lowering the price target to $200 from $245, the firm points to inline results and confident handling of inventory and manufacturing assets as strengths.

    • JPMorgan keeps an Overweight rating and adjusted its price target to $210 from $225, citing solid September quarter revenue and a continued belief in Texas Instruments’ long-term positioning. The “conservative” forward outlook is seen as a prudent response to macro uncertainty rather than a signal of execution issues.

    • Wolfe Research remains constructive, reiterating an Outperform rating with a $230 price target. The firm recognizes that recoveries are underway in most major end markets, with the exception of automotive, and sees prudent inventory and wafer start management as indicative of operational discipline.

    • Morgan Stanley suggests potential upside if low customer inventories drive replenishment, even as it takes a more reserved view overall. The firm acknowledges the flat recovery slope but points to eventual positive momentum as order trends improve.

    🐻 Bearish Takeaways

    • Mizuho downgraded Texas Instruments to Underperform, dropping the price target significantly to $150 from $200. The analyst raises concerns about the lack of near-term catalysts, premium valuation, slowing auto sales, ongoing competition in China, and tariff headwinds. Additionally, the company’s smaller footprint in high-growth segments like AI data centers is seen as a limitation.

    • Truist lowered its price target to $175 from $196 while maintaining a Hold rating, citing mixed quarterly results and fading margins. The analyst notes that while inventory levels have normalized, demand has not rebounded, and customers are not actively restocking, which limits prospects for near-term recovery.

    • Rosenblatt, while positive overall, highlights that margin pressures linked to reduced fab utilization are likely to persist in the short term as management seeks to balance inventory levels.

    • Morgan Stanley keeps an Underweight rating with a reduced target of $192 from $197, expressing caution over the underwhelming outlook for the September quarter and the challenging recovery trajectory presently facing the analog semiconductor sector, of which Texas Instruments is a key part.

    Continue Reading